Drug Information

Drug (ID: DG01589) and It's Reported Resistant Information

Name	NIBR3049
Synonyms	TCS 21311; 1260181-14-3; NIBR3049; TCS-21311; 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; CHEMBL1650951; NIBR3049NIBR3049; SCHEMBL16113848; NIBR-3049; DTXSID40678984; BDBM50335231; ZINC66103171; AKOS016355213; NCGC00387150-01; HY-108264; CS-0027898; FT-0674827; J-005320; JAK3/GSK-3beta/PKCalpha Inhibitor - CAS 1260181-14-3; 3-[5-[4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)pyrrole-2,5-dione; 3-{5-[4-(2-Hydroxy-2-methyl-propionyl)-piperazin-1-yl]-2-trifluoromethyl-phenyl}-4-(1H-indol-3-yl)-pyrrole-2,5-dione; 3-{5-[4-(2-Hydroxy-2-methylpropanoyl)piperazin-1-yl]-2-(trifluoromethyl)phenyl}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione Click to Show/Hide
Structure
Drug Resistance Disease(s)	Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases) Solid tumour/cancer [ICD-11: 2A00-2F9Z] [1]
Target	.	NOUNIPROTAC	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	4
IsoSMILES	CC(C)(C(=O)N1CCN(CC1)C2=CC(=C(C=C2)C(F)(F)F)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54)O
InChI	InChI=1S/C27H25F3N4O4/c1-26(2,38)25(37)34-11-9-33(10-12-34)15-7-8-19(27(28,29)30)17(13-15)21-22(24(36)32-23(21)35)18-14-31-20-6-4-3-5-16(18)20/h3-8,13-14,31,38H,9-12H2,1-2H3,(H,32,35,36)
InChIKey	CLGRAWDGLMENOD-UHFFFAOYSA-N
PubChem CID	50925411

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)			Click to Show/Hide
Key Molecule: Tyrosine-protein kinase JAK3 (JAK3)				[1]
Molecule Alteration	Missense mutation		p.V674A (c.2021T>C)	Molecule Info
Resistant Disease	Solid tumour/cancer [ICD-11: 2A00-2F9Z]			Disease Info
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	HEK293 cells	Kidney	Homo sapiens (Human)	CVCL_0045
	Ba/F3 cells	Colon	Homo sapiens (Human)	CVCL_0161
	U4C cells	Acetabulum	Homo sapiens (Human)	CVCL_D314
In Vivo Model	Balb/c bone marrow transplantation mouse model			Mus musculus
Experiment for Molecule Alteration	Western blotting analysis
Experiment for Drug Resistance	Proliferation assay

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)			Click to Show/Hide
Key Molecule: Tyrosine-protein kinase JAK3 (JAK3)				[1]
Molecule Alteration	Missense mutation		p.L857P (c.2570T>C)	Molecule Info
Sensitive Disease	Solid tumour/cancer [ICD-11: 2A00-2F9Z]			Disease Info
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	HEK293 cells	Kidney	Homo sapiens (Human)	CVCL_0045
	Ba/F3 cells	Colon	Homo sapiens (Human)	CVCL_0161
	U4C cells	Acetabulum	Homo sapiens (Human)	CVCL_D314
In Vivo Model	Balb/c bone marrow transplantation mouse model			Mus musculus
Experiment for Molecule Alteration	Western blotting analysis
Experiment for Drug Resistance	Proliferation assay

References

Ref 1	Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor SpecificitiesJ Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.